Secondary Cancer — Metastasis or Subsequent Malignancy

In general oncology practice, secondary cancer typically refers to metastatic cancer. In this setting, malignant cells break away from the primary site, travel through the bloodstream or lymphatic channels, and establish new tumours elsewhere. For instance, breast cancer cells colonising bone tissue remain breast cancer cells biologically, rather than converting into primary bone cancer.

Alternatively, clinicians use the term 'second primary malignancy' to describe a new, unrelated cancer arising later in life. These may occur because of genetic predispositions, persistent environmental exposures, or as a late complication of DNA-damaging cancer therapies such as ionising radiation and specific cytotoxic chemotherapies.

Distinguishing between metastatic progression and an independent second primary tumour fundamentally alters clinical decision-making. If a secondary lesion represents metastatic spread, systemic therapy aimed at the original biology remains the foundation of care, focusing on disease control and symptom preservation.

Conversely, if diagnostic testing reveals an unrelated second primary tumour, clinicians may initiate a separate, curative-intent regimen with distinct surgical, radiation, or targeted approaches. Recognising treatment-related risks also encourages long-term survivorship surveillance, enabling earlier detection and better overall outcomes.

Determining the origin of a secondary tumour relies heavily on diagnostic imaging and histopathological analysis. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) detect anatomical spread. A tissue biopsy is essential; pathologists perform immunohistochemistry and molecular profiling to compare tumour markers and genetic alterations with the primary malignancy, confirming lineage.

Secondary cancers can involve almost any malignancy. Metastatic secondary tumours frequently arise from common solid cancers, such as breast, bowel, lung, and prostate cancers, regularly spreading to bone, liver, lungs, or brain. Second primary malignancies frequently occur in survivors of Hodgkin lymphoma, childhood acute lymphoblastic leukaemia, and testicular cancers who received extensive alkylating chemotherapy or mantle radiotherapy decades prior.

Treatment hinges on whether the tumour is metastatic or a new primary cancer. Metastatic disease is managed with systemic therapies, including chemotherapy, targeted therapies, endocrine agents, and immunotherapy, supplemented by palliative radiotherapy. If confirmed as a second primary tumour, therapy is designed specifically for that novel cancer type, taking into account past radiation doses and cumulative chemotherapy limits.